Verana Health debuts Qdata Explorer in advance of American Academy of Ophthalmology 2024 Annual Meeting

(Image credit: AdobeStock/TGIF)

Verana Health is taking the wraps off several new products designed to enhance real-world insights and expedite treatment options in ophthalmology.

The company’s announcement comes ahead of the American Academy of Ophthalmology 2024 Annual Meeting, being held October 18 to 21, at McCormick Place in Chicago, Illinois.

According to the company, it is the data curation and analytics partner of the American Academy of Ophthalmology Intelligent Research in Sight (IRIS) Registry, which is the largest specialty society clinical data registry in all of medicine.

Among Verana Health’s new products is Qdata Explorer, a subscription-based tool that allows life sciences companies to explore Qdata, which are research-ready data modules that utilize exclusive, expertly-curated electronic health record (EHR) data from the Academy’s IRIS Registry. Using secure and advanced artificial intelligence (AI) technology, Verana Health transforms structured and unstructured healthcare data from EHRs into Qdata to power analytics solutions and software as a service products for real-world evidence generation.

Qdata Explorer’s intuitive dashboard enables users to easily build and share patient cohorts without needing coding skills. With visualizations that include patient characteristics, outcomes, and clinician subspeciality, life sciences companies can generate hypotheses and run feasibility studies faster. Qdata Explorer empowers every team member to contribute to making informed decisions and expedite treatment development.

“At Verana Health, we are continuously evolving our data and software solutions for both life sciences companies and clinicians to further accelerate research and medical innovations,” Sujay Jadhav, CEO of Verana Health, said in a statement. “Qdata Explorer is an innovative tool that increases access to our expansive, high-quality datasets that can unlock research insights along the entire drug development lifecycle and improve patient care.”

The company also announced the launch of Qdata Retinitis Pigmentosa (RP), as part of its Ophthalmology Qdata collection of fit-for-purpose modules that utilize RWD from the IRIS Registry to provide a comprehensive view of the patient journey. Confirming patients with RP using ICD and SNOMED codes alone does not provide an accurate way to identify patients with this inherited retinal disease.

However, by utilizing the RP diagnosis with clinician notes from EHRs and through imaging data, Verana Health’s Qdata Retinitis Pigmentosa enables more accurate identification of patients with this condition for pre- and post-approval studies. Qdata Retinitis Pigmentosa offers enhanced insights into patient outcomes, such as visual acuity and central subfield thickness.

According to the company, this can enhance patient identification, optimize trial design, improve site selection for clinical development, and help other life sciences teams understand disease activity with a clearer picture of treatment patterns and outcomes.

Specifically with clinicians in mind, Verana Health has also developed a new tool exclusively for Academy IRIS Registry participants. The tool, called Practice Insights, will allow ophthalmologists to help monitor, gauge and optimize several of their practice operations to identify outliers and areas of risk.

By leveraging these unique insights, clinicians can compare their practice’s performance on specific parameters with trusted peer benchmarks, including practice size, location, and subspecialty type. The intuitive, user-friendly platform makes it easy to help reduce audit risks, optimize several operations, and drive improvements.

A demonstration of Practice Insights will be provided to ophthalmologists and their teams during the AAO 2024 annual meeting.

Verana Health at AAO annual meeting

During the AAO 2024 annual meeting, joint Verana Health and Bausch + Lomb research will be available on demand. The research, titled “Reduction in IOP After Switching to Latanoprostene Bunod in Glaucoma Patients in Real-World Clinical Practice,” highlights the value of analyzing IRIS Registry data for open-angle glaucoma research.

The Verana Health team will deliver a session for clinicians on “How the IRIS Registry Can Help Navigate Changing MIPS Requirements” at 2:30 pm ET (3:30 pm CST) on Saturday, October 19, in the Academy Theater.

During the session, presenters will discuss how applying AI techniques to IRIS Registry data can help clinicians spend more time on patient care, while still meeting Merit-based Incentive Payment System requirements.